Quote:

---

Interestingly, what is not reported in today's PR is how the drugs performed in combination.

---

Leronlimab would not be synergistic with Resmetirom, downstream effects on T3 and T4 would be similar. With leronlimab at p = .01 (statistically significant) and Resmetirom at p = .057 (not statistically significant) the combo was almost certainly not better than leronlimab alone.

We know there are statistically significant results in humans at 350mg with 700mg most likely skewed. With this study showing that 700mg is much better than 350mg than I would expect better results with 700mg with a non-skewed trial. Why isn't the p value for leronlimab better? Most likely due to the low number of mice involved.